T-cellic intends to exploit current proprietary rights, add new intellectual properties and in-license or partner technologies in the area of T-cell-guided localisation and treatment of cancer.
URL: http://www.t-cellic.com/ in English [Translate]
T2C2 (Technology, Transfer, Commercialisation, Capital) has the mission to identify in Universities, Research Centres and Industry, business opportunities and turn them into real businesses.
URL: http://www.t2c2capital.com/ in English [Translate]
Tanabe Research Laboratories U.S.A., Inc. (TRL), is a wholly owned subsidiary of Tanabe Seiyaku Co., Ltd., headquartered in Osaka, Japan. TRL has a research group of approximately 32 employees which includes a current total of 16 PhD’s.
URL: http://www.trlusa.com/ in English [Translate]
Tapestry Pharmaceuticals, Inc. is a company focused on developing proprietary therapies for the treatment of cancer. We are also actively engaged in evaluating new therapeutic agents and related technologies for in-licensing.
URL: http://www.tapestrypharma.com/ in English [Translate]
Targa was founded in October, 2002 with the goal of commercializing Targa Therapeutic Payloads, molecules that can be conjugated or fused to antibodies or other tumor targeting molecules to improve their potency/toxicity ratio.
URL: http://www.targatherapeutics.com/ in English [Translate]
Marketplace for technology transfer. Databases and intellectual property resources provide searchable patent licensing opportunities, patent attorneys, venture capital sources, technology evaluations, and technology exchanges.
URL: http://www.teonline.com in English [Translate]
Provides engineered metal
finishes with plating processes
that address specific corrosion and wear related problems associated with chemical handling/processing.
URL: http://www.techmetals.com/ in English [Translate]